The Telegraph
Jobs slowdown threatens US economic recovery
A sharp slowdown in jobs growth has added to the pressure on President Biden as soaring wages and staff shortages threaten to hold back America’s economic recovery. Only 194,000 jobs were created in the US in September in the weakest reading this year.
MarketWatch
Chesapeake Energy’s stock rallies after getting bullish endorsement from UBS analyst
Shares of Chesapeake Energy Corp. rallied 1.9% in afternoon trading, after the oil and natural gas company received a bullish endorsement from UBS analyst Lloyd Byrne citing a “clean” balance sheet and discounted valuation. Byrne started coverage of Chesapeake with a buy rating and stock price target of $88, which implied a 35% upside from current levels. Since the company
Bloomberg
Argentina’s 120-Year-Old Cattle Auction Is Leaving Buenos Aires
(Bloomberg) — Argentina’s ranchers, cattle traders and gauchos, iconic figures in a country where grilling beef has long been a sacred ritual, are getting kicked out of Buenos Aires.Most Read from BloombergNYC’s Waldorf Gets Plush Renovation, Becomes Icon of China’s OverreachTycoon Behind a Crisis-Era Property Crash Now Sits on a $9 Billion Debt MountainBefore Interstates, America Got Around on InterurbansHow Singapore’s $50 Billion Financial District Will Change After Covid-19Amazon Delivery P
Benzinga
4 Stocks Insiders Are Selling
When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to go short on the stock. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision. Below is a look at a few recent notable insider sales. For more, check out Benzinga’s insider transactions platform. Twitter The Trade: Twitter, In
Reuters
Roche says Alzheimer’s therapy gets U.S. breakthrough designation
ZURICH (Reuters) -Roche said on Friday its gantenerumab antibody had received breakthrough therapy designation from the U.S. Food and Drug Administration for the treatment of Alzheimer’s disease. Like many other drug prospects to treat this debilitating disease, gantenerumab is designed to neutralise beta-amyloid plaques seen as a driver behind brain cell death. The Swiss pharmaceutical giant said the U.S. breakthrough designation was based on data showing that gantenerumab had significantly reduced brain amyloid plaque in ongoing trials.
MarketWatch
Fertilizer prices soaring as natural-gas rally adds to ‘perfect storm’
Fertilizer prices were already running red hot this year before a European energy crisis fanned the flames, potentially adding to a pinch on farmers in the U.S. and around the world and stoking worries about food inflation. “It’s almost like a perfect storm of different reasons that probably has a lot of upside in price for different macronutrients,” said Samuel Taylor, Cleveland-based executive director of research at Rabobank, in a phone interview. Natural gas is a key ingredient in the process used to make nitrogen-based fertilizers used on a range of crops, including corn and wheat.
Bloomberg
China’s ZM Logistics Is Exploring $1 Billion Sale
(Bloomberg) — Shanghai Zhengming Modern Logistics Co., a Chinese cold-chain logistics company backed by buyout firms, is exploring strategic options including a sale, according to people familiar with the matter.Most Read from BloombergNYC’s Waldorf Gets Plush Renovation, Becomes Icon of China’s OverreachTycoon Behind a Crisis-Era Property Crash Now Sits on a $9 Billion Debt MountainBefore Interstates, America Got Around on InterurbansHow Singapore’s $50 Billion Financial District Will Change A
Bloomberg
Senior Economist on the Jobs Number
Oct.08 — “Bloomberg Markets: Americas” with Alix Steel and Guy Johnson welcomed Elise Gould, Economic Policy Institute Senior Economist, to discuss the jobs report which came in well under estimates.
Reuters
Bayer blasts ‘unscientific’ rejection by Mexican regulator of GMO corn permit
MEXICO CITY (Reuters) -Bayer is evaluating its legal options after Mexican health regulators for the first time rejected a GMO corn permit it was seeking, the German pharmaceutical and crop science giant said in a statement to Reuters on Friday, blasting the decision as “unscientific.” Reuters reported earlier in the day that regulator Cofepris rejected the corn permit for future import as the government of President Andres Manuel Lopez Obrador hardens its opposition to genetically modified crops. “We are disappointed with the unscientific reasons that Cofepris used to deny the authorization,” the statement said, identifying the rejected corn variety as using its proprietary HT3 x SmartStax Pro technology.
